Cayston

Cayston is a brand name of aztreonam, approved by the FDA in the following formulation(s):

CAYSTON (aztreonam - for solution; inhalation)

• 
  Manufacturer: GILEAD
  
  Approval date: February 22, 2010
  
  Strength(s): 75MG/VIAL ^[RLD]

Has a generic version of Cayston been approved?

No. There is currently no therapeutically equivalent version of Cayston available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cayston. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Inhalable aztreonam aerosol for treatment and prevention of pulmonary bacterial infections
  Patent 7,208,141
  Issued: April 24, 2007
  Inventor(s): Montgomery; Alan Bruce
  Assignee(s): Corus Pharma, Inc.
  A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam, or a pharmaceutically acceptable salt thereof, delivered as an aerosol or dry powder formulation.
  
  Patent expiration dates:
  
  
  • December 20, 2021
    
    ✓ 
    Patent use: IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
    ✓ 
    Drug product
  
  



• 
  Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
  Patent 7,214,364
  Issued: May 8, 2007
  Inventor(s): Montgomery; Alan Bruce
  Assignee(s): Corus Pharma, Inc.
  A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
  
  Patent expiration dates:
  
  
  • December 20, 2021
    
    ✓ 
    Drug product
  
  



• 
  Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections
  Patent 7,427,633
  Issued: September 23, 2008
  Inventor(s): Montgomery; Alan Bruce
  Assignee(s): Gilead Sciences, Inc.
  A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
  
  Patent expiration dates:
  
  
  • December 20, 2021
    
    ✓ 
    Patent use: IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • February 22, 2017 - ORPHAN DRUG EXCLUSIVITY
  
  

See also...

• Cayston Consumer Information (Drugs.com)
• Cayston Consumer Information (Wolters Kluwer)
• Cayston inhalation Consumer Information (Cerner Multum)
• Cayston Advanced Consumer Information (Micromedex)
• Aztreonam Consumer Information (Wolters Kluwer)
• Aztreonam inhalation Consumer Information (Cerner Multum)
• Aztreonam injection Consumer Information (Cerner Multum)
• Aztreonam Inhalation Advanced Consumer Information (Micromedex)
• Aztreonam Intravenous, Injection Advanced Consumer Information (Micromedex)
• Aztreonam AHFS DI Monographs (ASHP)